Fig. (3) Suppression of HCV replication and/or dsRNA accumulation correlate with the preclusion of PKR activation. (A) Noninfected or JFH-1-infected Huh7.5.1 cells were treated with or without the CypI alisporivir, the HCV NS5A inhibitor daclatasvir or the HCV NS5B polymerase inhibitor sofosbuvir and subsequently treated with IFNα for 24 h. Cells were then lysed and analyzed for their content in viral and host proteins by Western blotting. (B) Non-infected cells were treated with the dsRNA mimic poly I:C (50 µg/mL) at the time of the cell plating, treated with or without the CypI alisporivir and IFNα 24 and 48 h post-cell plating, respectively. Cells were lysed 72 h postcell plating and analyzed for their content in viral and host proteins by Western blotting. Results are representative of 3 independent experiments.